• Users Online: 320
  • Print this page
  • Email this page


 
 
Table of Contents
ORIGINAL ARTICLE
Year : 2020  |  Volume : 11  |  Issue : 2  |  Page : 176-179

Bladder diseases: A histopathological study


1 Department of Pathology, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
2 Department of Surgery, Komfo Anokye Teaching Hospital, Kumasi, Ghana

Date of Submission02-Jun-2020
Date of Decision10-Sep-2020
Date of Acceptance02-Oct-2020
Date of Web Publication31-Dec-2020

Correspondence Address:
Dr. Babatunde M Duduyemi
Department of Pathology, Kwame Nkrumah University of Science and Technology, Kumasi
Ghana
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/atp.atp_33_20

Get Permissions

  Abstract 


Background: There is a dearth of publications on the histopathological findings from the bladder specimen in this country. Knowledge of the profile of histological findings from bladder biopsies will help reveal the most common lesions, the demographical distribution as well as the association of clinical symptoms with various conditions and interventions to be made. Methodology: This was a retrospective, histopathological study conducted over a period of 10 years. Demographics of the patient were abstracted, and slides were reviewed to establish the diagnoses on bladder biopsies. Results: There were 180 cases of bladder lesions studied. Males accounted for 86 (47.78%), and females recorded 94 (52.22%) of the cases. The modal age group is 50–59, with 42 cases. The mean age is 54.14 ± 18.62. Inflammatory (nonneoplastic) lesions accounted for 53 (29.44%) and neoplastic lesions accounted for 127 (70.56%), of which benign lesions (squamous papilloma) were 13 (10.24%) whereas malignant cases were 114 (89.76%). Urothelial carcinoma of the bladder was the most common bladder malignancy (57%) and squamous cell carcinoma (35.96%). Lymphoma, rhabdomyosarcoma, carcinoma in situ, and adenocarcinoma were relatively rare. Most of the tumors were high grade. Conclusion: Bladder diseases are more common in females in our center, and most of the neoplastic lesions are high-grade carcinomas.

Keywords: Bladder biopsy, inflammatory lesions, neoplastic, schistosomiasis


How to cite this article:
Duduyemi BM, Ayibor WG, Azorliade R, Safo F, Owusu E. Bladder diseases: A histopathological study. Ann Trop Pathol 2020;11:176-9

How to cite this URL:
Duduyemi BM, Ayibor WG, Azorliade R, Safo F, Owusu E. Bladder diseases: A histopathological study. Ann Trop Pathol [serial online] 2020 [cited 2021 Apr 19];11:176-9. Available from: https://www.atpjournal.org/text.asp?2020/11/2/176/305691


  Introduction Top


Diseases of the bladder include inflammatory lesions that are usually caused by the infections of the lower urinary tract and in most cases, serve as precursor to malignancies of the bladder. Infections that cause inflammation of the bladder account for 30%–45% of all bladder diseases and range from mild chronic inflammations and abscesses to acute cystitis. In developing countries, infection with Schistosoma sp. as seen in Africa and parts of Asia is responsible for the inflammation of the bladder that sometimes leads to bladder malignancy.

There are over 12 million new cases of cancer reported worldwide every year, with close to 5.4 and 6.7 million occurring in developed and developing countries, respectively.[1],[2] Cancer of the bladder is the ninth most common diagnosed cancer globally.[3] Among the prominent risk factors is smoking,[4],[5] and in developed countries, smoking habit accounts for 50% and 35% of bladder cancers in males and females, respectively.[6] It has been reported that, carcinogenic substances excreted in the urine can produce malignant papillary tumors in the bladder. In addition, chronic urinary infection caused by schistosomiasis or bilharziasis (Schistosoma hematobium), which is a tropical disease, is associated with the development of squamous cell carcinoma of the bladder.[7] Similar to all cancers, the clinical management and prospects of the disease are reliant upon the stage at which it is first noticed.[8]

Histologically, noninvasive lesions at the time of diagnosis are usually categorized into the subtypes: papillary and nonpapillary (carcinoma-in-situ). Typically, superficial papillary tumors are low-grade and behave much less aggressively; however, the latter, usually aggressive, high-grade lesions and almost always progress to invasive cancer.[9] Like most other malignancies, pathological stage and histological features, including grade of tumor, are the important independent predictors of the prognosis.[10],[11],[12] Studies in the last decade have shown a paradigm shift in the risk factors for bladder malignancies, such as precursor inflammatory lesions, infections by Schistosoma hematobium , developmental anomalies, and particularly smoking habit from developed to developing countries, especially low- and middle-income countries such as Ghana. This predicts a concurrent increase in bladder malignancies incidence in such communities in the next decade or so.[13],[14] The aim of the present study was to examine the histopathological features of bladder specimen to reveal the spectrum of lesions in patients diagnosed with various indications for bladder biopsy at Komfo Anokye Teaching Hospital (KATH) in the Ashanti region of Ghana.


  Methodology Top


KATH, Department of Pathology is the study site, and it is the major referral hospital in the area. The present study employs a retrospective design with data and archived slides extracted from our center from 2009 to 2018.

Slides of tissue samples were first screened histologically and diagnoses confirmed by a consultant pathologist. Tumors were classified based on the WHO (2010, 4th edition) histological classification of tumors of the bladder. Data on demographics were also retrieved from the archived request forms.

Histopathology request forms, reports, and H and E slides of all bladder biopsies received during the study period were extracted and used for the study. A total of 180 suitable bladder cases were available for the study period.

All cases with retrieved slides and adequate information were selected for the study; cases in which the slides confirmed the histological diagnosis after histological screening were used. Cases in which the H- and E-stained slides could not be retrieved or the reports have inadequate information were totally excluded from the study. In all, 203 cases were retrieved for the study with 180 of them meeting the eligibility criteria and were used for the study. Twenty-three were discarded for having inadequate information.

Ethical approval

The committee on Human Research Publication and Ethics of the School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology and the KATH, Kumasi gave approval for the study.


  Results Top


Age and sex distribution of bladder lesions

There were 180 cases studied over a period from 2009 to 2018. The peak age of occurrence of bladder lesions was 50–59 years with a mean of 54.14 ± 18.62. The male-to-female ratio was 1:1.09. Neoplastic cases were generally predominant over nonneoplastic or inflammatory lesions. They accounted for 70.56% of all cases with malignant cases accounting for 63.33% of all cases. The results are summarized in [Table 1].
Table 1: Age and sex distribution for type of bladder lesion

Click here to view


Inflammatory lesions of the bladder

There were 53 inflammatory cases comprising mild chronic bladder inflammation, abscess, and acute cystitis glandularis, altogether representing 29.44% of all cases. There was no significant difference between in the frequency of occurrence in males and females as both had almost the same number of cases. Cystitis of the bladder was the most common inflammatory lesion with 38 (71.70%) of cases and schistosomal cystitis constituting 14 cases (26.41%). [Table 2] gives a summary of the distribution of inflammatory lesions.
Table 2: Distribution of inflammatory lesions

Click here to view


Distribution of malignant bladder tumors

Malignant bladder tumors accounted for most of our cases with 63.33% of all cases. Urothelial carcinoma of the bladder was the most common histological type with 65 cases, representing 57% of all malignancies and squamous cell carcinoma accounting for 35.96% (41 cases). Lymphoma (non-Hodgkin's), rhabdomyosarcoma, carcinoma in situ, and adenocarcinoma were the other histological types of bladder malignancies with 1 (0.88%), 2 (1.76%), 3 (2.64%), and 2 (1.76%) cases, respectively. [Figure 1] depicts the distribution of bladder malignancies by frequency.
Figure 1: Gender and histologic types of malignant bladder tumors

Click here to view


Histologic grading of bladder cancer

High-grade cancers were the dominant histological classification of bladder malignancies with 67 (63.21%) of cases, of which 55 (51.89%) were poorly differentiated and 12 cases representing 11.32% were moderately differentiated. Low-grade tumors (well differentiated) accounted for 39 (36.79%). [Figure 2] gives a pictorial distribution of the histological grades of malignant cases.
Figure 2: Histological grading of urothelial and squamous cell carcinoma of the bladder

Click here to view



  Discussion Top


Inflammatory lesions of the bladder, usually caused by infections of the lower urinary tract and in most cases, serve as precursor to malignancy of the bladder accounts for about 39% of all bladder disorders according to the study and range from mild chronic inflammation and abscess to acute cystitis glandularis. Infection with Schistosoma sp. in Africa and parts of Asia, as seen from this study, is responsible for inflammation of the bladder and consequently, bladder malignancy.[15],[16] According to Johansson and Cohen,[17] it accounts for over 75% of all bladder cancers, usually squamous cell carcinoma of the urinary bladder.

Bladder cancer is one of the most common cancers since 1991 when it was found to be the second most common genitourinary malignancy in a report by Klufio.[18] Bladder cancer is a common urologic cancer that has the highest recurrence rate of any malignancy. Bladder cancers affect more females than males per our findings, which contrast to work done by Mayo Clinic Staff in America, which presented more bladder cancer cases in males than females.[19] The peak age group of occurrence of 50–59 years is in line with several studies not only on bladder cancer but numerous other malignancies. It is no surprise, therefore, that neoplastic lesions of which malignant ones predominate, represented the most common lesions from the study. Inflammatory nonneoplastic lesions, primarily, chronic cystitis caused by Schistosoma hematobium , were also common from the study. This is not unusual as several other studies in Africa reported schistosoma-related inflammatory lesions of the bladder.[16] Urothelial carcinoma of the bladder was the most common histologic type of bladder malignancies, according to our study and represents more than 50% of cases. This finding correlates with several other works, which recorded similar trends. In a study by Umbreit et al . of Mayo Clinic in America, they recorded a higher rate of urothelial carcinoma.[19] and confirmed by Kos, who also posited that urothelial carcinoma or transitional cell carcinoma (TCC) is by far the most common type of bladder malignancy.[20] The trend was further consolidated by a report by Razmaria,[21] and Babjuk et al .[22] who reported on a similar result. This, however, is still very low compared to the 90% urothelial/TCC and 3% squamous cell carcinoma of the bladder reported by Metts et al .[23] in an American population. They reported very high squamous cell carcinoma in Egypt (75%), an African population, hence agreeing with findings from our study, which proved with adequate information that squamous cell carcinoma is one of the most common bladder malignancies, accounting for 35.96% of the cases despite trailing urothelial carcinoma. Even though our findings is backed by previous study which also reported squamous cell carcinoma to be the second most common bladder malignancy,[24] there is a huge difference in the incidences between our findings and theirs, 1%–2% compared to the 36% recorded in our study. The difference in the occurrence of this type of cancer may be due to the several factors such as race, weather, environment, and diet among other factors, an assertion that is shared by Farhood et al . in their study in Iran.[25] Al-Samawi and Aulaqi also reported 17% of Squamous cell carcinoma (SCC) in Oman,[26] while a study in England also reported only 1% of SCC in bladder cancers[27] and 7% was recorded in the United States.[28]

Carcinoma in situ , adenocarcinoma, rhabdomyosarcoma, and lymphoma (non-Hodgkin lymphoma) were the other histological types of bladder malignancies recorded and were observed in decreasing order of prevalence, respectively (2.64%, 1.76%, 1.76%, and 0.88%). These are usually rare types of bladder cancers, and their prevalence is similar across several other studies, like what was reported in Oman,[26] where the prevalence of these rare bladder malignancies is to our study. Preponderance of high-grade cancers was evident as the study recorded about two-third of the cases. This finding is similar to other studies in Africa and beyond. Low-grade cancers are usually seen in the younger age group and high grade in older ones as revealed in our study in which most of our patients are in the sixth decade of life.[23],[29] The female preponderance of squamous cell carcinoma in our study contrasts the work of Metts et al . who found males to be 2–3 times more susceptible than females.[23]


  Conclusion Top


Bladder lesions are more common in females than males, and bladder masses were the most common indication for biopsy in our center. While urothelial carcinoma was the most common bladder malignancy in our study, most of them are high-grade tumors and require interventional measures. Chronic cystitis with bladder cancer, especially schistosomal cystitis was observed in the study. Early screening for bladder lesions and treatment of disorders should be encouraged to prevent neoplastic transformation.

Acknowledgement

We acknowledge the support from staff of the Pathology Department, KNUST.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al . Global Cancer Facts and Wgs. Atlanta: American Cancer Society; 2007.  Back to cited text no. 1
    
2.
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. No. 5.ver. 2.0. Lyon: IARC Cancer Base, IARC Press; 2004.  Back to cited text no. 2
    
3.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol 2017;71:96-108.  Back to cited text no. 3
    
4.
Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality. Eur Urol 2014;66:59-73.  Back to cited text no. 4
    
5.
van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: A meta-analysis of 89 observational studies. Int J Epidemiol 2016;45:857-70.  Back to cited text no. 5
    
6.
Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies. Cancer 2000;89:630-9.  Back to cited text no. 6
    
7.
Felix AS, Soliman AS, Khaled H, Zaghloul MS, Banerjee M, El-Baradie M, et al . The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control 2008;19:421-9.  Back to cited text no. 7
    
8.
National Cancer Institute. SEER Database: Available from: http://www.seer.cancer.gov/publications/survival/surv_bladder.pdf. [Last accessed on 2019 Aug 21].  Back to cited text no. 8
    
9.
Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone-Macaluso M, et al . Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995;31A: 1840-6.  Back to cited text no. 9
    
10.
Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5.  Back to cited text no. 10
    
11.
Delclos GL, Lerner SP. Occupational risk factors. Scand J Urol Nephrol Suppl 2008;42:58-63.  Back to cited text no. 11
    
12.
European Association of Urology Guidelines for Non-Muscle-Invasive Bladder Cancer; 2018.  Back to cited text no. 12
    
13.
Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003;362:847-52.  Back to cited text no. 13
    
14.
Ezzati M, Lopez AD. Measuring the accumulated hazards of smoking: Global and regional estimates for 2000. Tob Control 2003;12:79-85.  Back to cited text no. 14
    
15.
Lemmer LB, Fripp PJ. Schistosomiasis and malignancy. South Afr Med J 1994;84:211-5.  Back to cited text no. 15
    
16.
Sur M, Cooper K. Schistosoma hematobium and bladder cancer. In: Totowa, NJ, editor. Infectious Causes of Cancer. SpringerLink: Humana Press; 2000. p. 435-48.  Back to cited text no. 16
    
17.
Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997;13:291-8.  Back to cited text no. 17
    
18.
Klufio G. A review of genitourinary cancers at the Korle-Bu Teaching Hospital Accra, Ghana. West Afr J Med 2004;23:131-4.  Back to cited text no. 18
    
19.
Umbreit EC, Crispen PL, Shimko MS, Farmer SA, Blute ML, Frank I. Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma. Cancer 2010;116:3399-407.  Back to cited text no. 19
    
20.
Kos LG. Tumors of the Urinary Bladder. Armed Forces Institute of Pathology; 1975.  Back to cited text no. 20
    
21.
Razmaria AA. JAMA patient page. Bladder Cancer. JAMA 2015;314:1886.  Back to cited text no. 21
    
22.
Babjuk M, Oosterlinck W, Sylvester R, Kaasine E, Bhle A, Palou-Redorta J, et al . EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Europ Urol 2011;59:997-1008.  Back to cited text no. 22
    
23.
Metts MC, Metts JC, Milito SJ, Thomas CR. Bladder cancer: A review of diagnosis and management. J Natl Med Assoc 2000;92:285-94.  Back to cited text no. 23
    
24.
Brauers A, Jakse G. Epidemiology and biology of human urinary bladder cancer. J Cancer Res Clin Oncol 2000;126:575-83.  Back to cited text no. 24
    
25.
Farhood B, Raei B, Malekzadeh R, Shirvani M, Najafi M, Mortezazadeh T. A review of incidence and mortality of colorectal, lung, liver, thyroid, and bladder cancers in Iran and compared to other countries. Contemp Oncol (Pozn) 2019;23:7-15.  Back to cited text no. 25
    
26.
Al-Samawi S, Aulaqi SM. Urinary bladder cancer in Yemen. Oman Med J 2013;28:337-40.  Back to cited text no. 26
    
27.
Lynch CF, Cohen MB. Urinary system. Cancer 1995;75 Suppl 1:316-29.  Back to cited text no. 27
    
28.
Costello AJ, Tiptaft RC, England HR, Blandy JP. Squamous cell carcinoma of bladder. Urology 1984;23:234-6.  Back to cited text no. 28
    
29.
Salem HK, Mahfouz S. Changing patterns (age, incidence, and pathologic types) of schistosoma-associated bladder cancer in Egypt in the past decade. Urology 2012;79:379-83.  Back to cited text no. 29
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Abstract
Introduction
Methodology
Results
Discussion
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed198    
    Printed18    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal